U.S. markets close in 4 hours 42 minutes

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.76-0.04 (-0.59%)
As of 11:18AM EST. Market open.

Jounce Therapeutics, Inc.

780 Memorial Drive
Cambridge, MA 02139
United States
857 259 3840
http://jouncetx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees129

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard MurrayPres, CEO & Director845.1kN/A1959
Mr. Hugh M. ColeChief Bus. Officer & Head of Corp. Devel.561.11kN/A1965
Dr. Elizabeth G. TrehuChief Medical Officer555.66kN/A1960
Dr. James P. AllisonFounderN/AN/AN/A
Dr. Thomas F. GajewskiFounderN/AN/AN/A
Dr. Robert D. SchreiberFounderN/AN/AN/A
Dr. Drew Mark Pardoll M.D., Ph.D.FounderN/AN/AN/A
Dr. Padmanee SharmaFounderN/AN/AN/A
Dr. Louis M. WeinerFounderN/AN/A1952
Ms. Kimberlee Cobleigh Drapkin CPA, CPACFO & TreasurerN/AN/A1968
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.